Physician profile
Thomas Hess
NPI 1487855250
$2,977.47
in general payments reported to CMS, 2019-2025
30 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $633 · 2021: $356 · 2022: $252 · 2023: $332 · 2024: $468 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $923.63 | 2019-2025 | |
| Amgen INC. | $277.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $234.25 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $145.88 | 2022-2024 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $140.26 | 2020-2024 | Farxiga |
| Abbvie INC. | $132.69 | 2020-2025 | |
| Almatica Pharma LLC | $129.39 | 2021-2025 | Loreev Xr, Teriparatide |
| Kowa Pharmaceuticals America, INC. | $96.98 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $91.48 | 2019-2023 | Verquvo, Steglatro |
| Sanofi-Aventis U.S. LLC | $90.46 | 2019-2021 | |
| Edwards Lifesciences Corporation | $81.15 | 2021 | |
| Boston Scientific Corporation | $71.44 | 2022-2025 | General - Pain Management, Artisan |
| Novartis Pharmaceuticals Corporation | $69.01 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $60.34 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $51.23 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $50.03 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $44.19 | 2020 | |
| Daiichi Sankyo INC. | $39.88 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.31 | 2019-2020 | |
| Abbott Laboratories | $31.09 | 2021-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $28.00 | 2019 | |
| Kyowa Kirin, INC. | $22.01 | 2023 | |
| Galderma Laboratories, L.P. | $17.89 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $17.37 | 2019 | |
| Ethicon US, LLC | $17.26 | 2019 | |
| Lucid Diagnostics INC. | $16.03 | 2022 | |
| Lilly USA, LLC | $15.78 | 2024 | Mounjaro |
| Azurity Pharmaceuticals, INC. | $15.41 | 2023 | Edarbi |
| Sumitomo Pharma America, INC. | $15.01 | 2023 | Gemtesa |
| Eisai INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.